Fulgent Genetics Balances Growth Ambitions With Profit Strain

Fulgent Genetics ((FLGT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Fulgent Genetics’ latest earnings call revealed a company in transition, balancing solid revenue growth and innovative expansion against mounting near‑term profitability pressures. Management struck a cautiously optimistic tone, pointing to platform advances, M&A and a strong balance sheet, while warning that 2026 margins and earnings will be hit by customer churn and higher investment spending.

Full-Year Revenue Growth and Overall Performance

Fulgent delivered full‑year 2025 revenue of $322.7 million, up about 14% year over year and ahead of many expectations for a post‑pandemic diagnostics slowdown. Management framed this as evidence that its diversified testing and services portfolio is gaining traction, even as the business shifts away from COVID‑era volumes toward more sustainable, higher‑value offerings.

Quarterly and Segment Strength Across the Portfolio

Fourth‑quarter 2025 revenue came in at $83.3 million, up 9% year over year but slightly down sequentially as anticipated. Precision Diagnostics led with $48.2 million in Q4 sales, while Anatomic Pathology delivered $27 million and Biopharma Services $8.1 million, with full‑year biopharma revenue jumping 58% to $25.8 million.

Gross Margin Expansion and 2026 Margin Outlook

Non‑GAAP gross margin reached 41% in Q4, with GAAP gross margin at 39.1%, reflecting benefits from lab efficiencies and streamlined operations. Management expects 2026 non‑GAAP gross margins to stay slightly above 40% overall, though margins should dip in the first half before improving in the back half as volumes and mix normalize.

Product and Platform Innovations Drive Differentiation

The company highlighted launches of RNA‑integrated whole genome sequencing and ultra‑rapid whole genome sequencing as key differentiators in advanced diagnostics. Fulgent also rolled out its in‑house digital pathology platform, Ezeopath, achieving nearly 100% digital case reading and seeding a pipeline of AI modules planned for deployment through 2026.

Regulatory Approvals Open New Market Opportunities

Fulgent secured New York State approvals for its proprietary non‑invasive prenatal test, Nova, and its whole genome sequencing test during Q4. These approvals unlock access to one of the most highly regulated and commercially important U.S. markets, bolstering the company’s growth potential in reproductive health and genomic testing.

M&A Strategy to Reduce Customer Concentration Risk

To address heavy dependence on a single customer, Fulgent announced plans to acquire Bako Diagnostics and StrataDx for roughly $55.5 million, with closing expected in March 2026. Management projects these deals will add about $50 million to $55 million of 2026 revenue and reduce any single‑customer exposure to less than 10% of total sales.

Therapeutics Pipeline Adds Long-Term Optionality

In therapeutics, the FID‑7 program completed Phase 2 enrollment in 46 patients, with early efficacy and safety described as encouraging and a Phase 3 protocol under development for a potential 2027 start. Meanwhile, FID‑22 is progressing through Phase 1 dose escalation, with a third dose level under way and a maximum tolerated dose readout anticipated later in 2026.

Strong Liquidity Provides Cushion for Investments

Fulgent ended 2025 with about $755.5 million in cash, restricted cash and marketable securities, giving management confidence to fund R&D, acquisitions and platform build‑out despite near‑term losses. Even after planned deal closings and investment, year‑end 2026 cash is forecast between roughly $606 million and $685 million, assuming the delayed tax refund is received.

Loss of Largest Customer Creates Near-Term Revenue Hit

The company’s largest customer contributed $70.8 million in 2025, or about 22% of revenue, but is bringing much of its testing volume in‑house. Fulgent expects revenue from this customer to fall to around $11.8 million in the first half of 2026, implying a roughly $59 million hit and adding significant pressure to revenue growth and gross margins.

Widening GAAP Loss and EBITDA Weakness

Profitability deteriorated in Q4 as the GAAP net loss widened to $23.4 million from $6.6 million in the prior quarter. Adjusted EBITDA swung to a loss of about $4.5 million from a modest $0.7 million gain in Q3, underscoring the cost of growth initiatives and the strain from shifting volume dynamics.

Non-GAAP Operating Margin and 2026 Profitability Pressure

Non‑GAAP operating margin slipped to negative 10.7% in Q4, reflecting rising operating costs relative to revenue. Management now expects 2026 non‑GAAP operating margin to deteriorate further to roughly negative 18%, driven by acquisition‑related expenses, expanded sales efforts and increased R&D and therapeutics spending.

Operating Expenses Surge on Investments and One-Time Charges

GAAP operating expenses jumped to $68.8 million in Q4 from $50.9 million in the previous quarter, reflecting higher payroll and integration‑related costs. The quarter also absorbed a one‑time professional liability charge of $14.5 million, amplifying the headline increase in operating expenses and deepening the reported loss.

EPS Outlook Highlights Near-Term Earnings Drag

The company guided full‑year 2026 non‑GAAP EPS to a loss of $1.45 per share, excluding stock‑based compensation, acquisition costs and amortization and impairment. This outlook signals a meaningful step‑down from 2025 levels as Fulgent prioritizes growth, M&A and pipeline development over near‑term earnings.

Biopharma Services: Growth in 2025, Pullback in 2026

Despite delivering 58% growth in 2025 to $25.8 million, biopharma services are expected to retrench to about $20 million in 2026. Management cited long and unpredictable sales cycles in this segment, suggesting revenue could be lumpy even as the strategic relevance of biopharma partnerships remains high.

Delayed Tax Refund Adds Timing Uncertainty

A federal income tax refund of around $106 million has been delayed, a consequence of the 2025 government shutdown. While this does not threaten Fulgent’s liquidity given its sizable cash position, it adds an element of timing uncertainty to the company’s cash flow and year‑end balance projections.

Back-Loaded 2026 Revenue and Execution Risk

Fulgent expects 2026 revenue to be heavily back‑loaded, with roughly $158 million to $159 million in the first half and $191 million to $192 million in the second half. This pattern reflects the rapid loss of its largest customer early in the year and the later contribution from Bako and StrataDx, raising execution risk around integration and ramp‑up.

Forward-Looking Guidance and Strategic Trajectory

For 2026, Fulgent guided to about $350 million in revenue, representing roughly 8.5% growth on the reported base, with underlying growth excluding the largest customer and assuming deals close closer to 31%. Anatomic pathology is expected to surge to about $162 million, non‑GAAP gross margins should hold just above 40%, and cash is projected to remain strong even as the company spends on therapeutics, capex and integration.

Fulgent Genetics’ earnings call painted a picture of a company leaning into innovation and acquisitions to build a more diversified, durable business, even at the cost of near‑term profits. Investors will be watching closely to see whether management can offset the loss of its largest customer, execute on M&A and maintain margins, setting up a stronger, more balanced growth profile beyond 2026.